From Stu Innes

Rachel Holden

To:

Rachel Holden; John Hancock
Re: December IPAG meeting [EIAut-ELCOMM.FID43809] Subject: Tuesday, 10 November 2020 9:19:27 am

Date: Attach

image004.jpg


Hi both.

Thanks for the opportunity on this, but I'm not sure there's much I can add on those questions. However, I think I have two points that are worth making from our experience:

- Transperancy is critical. For a party thinking of making an investment decision in DER/Flexibility it's important that they can get ready access to historical data around pricing so that they can take a view on what the future revenue for their investment might be (and eventually, ideally, a forward curve). Transpower seemed to have difficulty providing this, or at least anything that was provided seemed to be a bit of a scramble to pull together as an afterthought, and with all sorts of issues regarding confidentiality and identification of parties through their nodes.. This then feeds the next, more important point.
- Transpower is likely to be a significant player in the market for flexibility (as is any given EDB when it comes to their own footprint). In what is an emerging market for flexibility marketplace platforms and systems, there is a high likelihood that we'll see distortions if large buyers of flexibility are also a potential player in the market platform market.

I'm not sure there'd be value in me presenting to the group on those two points. I'd imagine they've come up before, so probably the value is in having them reiterated above.

Apologies, I'd drafted but not sent this prior to your follow up Rachel.



| Senior Consultant |
|---|
| |
| Electricity Authority - Te Mana Hiko |
| Level 7, Harbour Tower, 2 Hunter Street |
| PO Box 10041 |
| Wellington 6143 |
| New Zealand |
| www.ea.govt.nz |
| - |
| |
| |
| |
| |
| The information contained in this transmission is confidential. |

"The information contained in this transmission is confidential. It is intended for the named addressee only. If you are not the named addressee you may not copy, distribute or take any action in reliance upon this transmission."